Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to observe the changes of intestinal microbiota after deep brain stimulation (DBS) therapy for Parkinson's disease, and explore the role of intestinal microbiota in the neuroprotective effect of DBS.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in gut microbiota | Analyzed by 16sRNA sequencing of feces | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Change in gut microbiota | Analyzed by 16sRNA sequencing of feces | Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood biomarkers of neuroinflammation and alpha-synuclein | Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Change in blood biomarkers of neuroinflammation and alpha-synuclein |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with Parkinson's disease and are expected to undergo DBS therapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ling Zhou | Contact | +8615895918786 | lingzhou531@foxmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Cunming Liu | The First Affiliated Hospital with Nanjing Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| the Hospital Research Ethics Committee of the First Affiliated Hospital of Nanjing Medical University | Recruiting | Nanjing | Jiangsu | 210029 | China |
Not provided
Not provided
Not provided
Not provided
Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein |
| Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |
| Frequency of defecation | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Frequency of defecation | Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |
| Dosage of anti-Parkinson's agent | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Dosage of anti-Parkinson's agent | Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |
| Change in the score of Unified Parkinson's Disease Rating Scales | It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe. | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Change in the score of Unified Parkinson's Disease Rating Scales | It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe. | Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |
| Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39) | Change in PDQ-39 scores, higher scores mean a worse outcome | Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy |
| Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39) | Change in PDQ-39 scores, higher scores mean a worse outcome | Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy |